GeoVax Labs (GOVX) AI Stock Analysis

• Market Cap: $15.65M
• Dividend Yield: N/A
• Average Volume (3M): 310.96K
• Price to Earnings (P/E): ―
• Beta (1Y): 3.03
• Revenue Growth: N/A
• EPS Growth: 71.39%
• Country: US
• Employees: 17
• Sector: Healthcare
• Sector Strength: 55
• Industry: Biotechnology
• EPS (TTM): -0.45
• Shares Outstanding: 15,193,593
• 10 Day Avg. Volume: 465,813
• 30 Day Avg. Volume: 310,961
• PEG Ratio: -0.02
• Price to Book (P/B): 1.79
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.72
• Enterprise Value/Market Cap: 0.67
• Enterprise Value/Revenue: 0.80
• Enterprise Value/Gross Profit: 8.11
• Enterprise Value/Ebitda: -0.10
• 1Y Price Target: $11.70
• Price Target Upside: 786.36% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 34 Underperform
• Price Target: ―

GeoVax Labs is navigating substantial financial and operational challenges, reflected in its low financial performance score. While there are positive developments in vaccine advancements and strategic partnerships, the negative impact of the BARDA contract termination and bearish technical indicators weigh heavily on the overall score.

Positive Factors

Clinical Studies

Additional data announcements from clinical studies with 04S1 could be positive catalysts through 2025.

Comparative Analysis

DSMB Review Suggests GEO-CM04S1 May Be Superior to mRNA Vaccine.

Vaccine Development

GEO-CM04S1 booster studies to continue, with early clinical studies showing the vaccine induces durable neutralizing antibody and T-cell-based immunity against current and future variants of SARS-CoV-2.

Negative Factors

Contract Termination

Termination of the contract will not have a long-term material effect.

Project Termination

GeoVax Labs announced it received written notification from Advanced Technology International directing GeoVax to stop work on all efforts with respect to a Rapid Response Partnership Vehicle project.

GeoVax Labs Business Overview & Revenue Model

Company Description

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.

How the Company Makes Money

GeoVax Labs generates revenue through a combination of government and non-governmental grants, collaborative research and development agreements, and potential licensing deals. The company partners with various organizations and institutions to advance its vaccine candidates, often receiving funding and milestone payments in return. GeoVax also seeks to monetize its vaccine platform through licensing agreements with other biotech or pharmaceutical companies, allowing them to use the technology for their own product development. Revenue may also be derived from future product sales as vaccines progress through clinical trials and achieve regulatory approval.

GeoVax Labs Financial Statement Overview

Summary

GeoVax Labs faces significant financial challenges with no revenue growth and continuous net losses, reflecting operational and market difficulties. The company's strong cash position offsets some risks, but negative cash flows and reliance on financing indicate potential financial instability.

Income Statement

GeoVax Labs has consistently reported zero or negligible revenue, indicating a significant challenge in generating sales. The company has experienced persistent net losses with negative EBIT and EBITDA margins, reflecting operational inefficiencies and high costs relative to its revenue base.

Balance Sheet

The balance sheet shows a relatively strong cash position with no debt, which is a positive sign of financial prudence. However, the equity ratio is weak due to a low level of total assets and historical negative equity, posing risks to financial stability and growth potential.

Cash Flow

GeoVax Labs exhibits negative operating and free cash flow, indicating potential cash management issues. The company relies heavily on financing activities to support its operations, raising concerns about sustainability and the need for continued external funding.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
5.59M	3.95M	0.00	81.00K	385.00K	1.82M
	Gross Profit
1.29M	3.86M	-20.72M	24.72K	-15.17M	-621.46K
	EBIT
-24.67M	-25.14M	-26.74M	-14.03M	-18.75M	-2.82M
	EBITDA
-24.43M	-24.88M	-26.67M	-13.97M	-18.53M	-2.79M
	Net Income Common Stockholders
-24.50M	-24.99M	-25.97M	-14.01M	-18.53M	-2.94M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
20.84M	5.51M	6.45M	27.61M	11.42M	9.88M
	Total Assets
21.12M	8.16M	9.28M	31.35M	11.80M	10.39M
	Total Debt
195.00K	0.00	0.00	0.00	0.00	198.06K
	Net Debt
-20.65M	-5.51M	-6.45M	-27.61M	-11.42M	-9.69M
	Total Liabilities
464.11K	3.11M	3.52M	4.75M	7.43M	825.00K
	Stockholders Equity
20.65M	5.05T	5.76M	26.60M	4.36M	9.57M
Cash Flow		Free Cash Flow
-24.98M	-24.70M	-25.22M	-19.16M	-11.24M	-2.91M
	Operating Cash Flow
-24.96M	-24.68M	-25.17M	-19.03M	-11.20M	-2.75M
	Investing Cash Flow
-37.55K	-20.65B	-48.95K	-134.26K	-47.72K	-156.79K
	Financing Cash Flow
31.66M	23.75M	4.06M	35.35M	12.78M	12.51M

GeoVax Labs Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.32
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GOVX, the sentiment is Positive. The current price of 1.32 is above the 20-day moving average (MA) of 1.09, above the 50-day MA of 1.00, and below the 200-day MA of 1.92, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 64.67 is Neutral, neither overbought nor oversold. The STOCH value of 42.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GOVX.

GeoVax Labs Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADXN	54 Neutral	$13.95M	0.87	-92.60%	―	-74.52%	―
Sector *	54 Neutral	$5.34B	3.27	-45.10%	3.30%	16.80%	0.02%
MBRX	44 Neutral	$9.68M	―	-214.79%	―	―	52.82%
ABVC	43 Neutral	$30.06M	―	-27.00%	―	1904.43%	93.72%
PHIO	42 Neutral	$10.89M	―	-76.12%	―	―	81.71%
SNSE	40 Underperform	$7.56M	―	-64.18%	―	―	1.00%
GOVX	34 Underperform	$15.65M	―	-616.17%	―	―	71.39%

GeoVax Labs Corporate Events

GeoVax Labs Faces Contract Termination for COVID-19 Vaccine

On April 11, 2025, GeoVax Labs received a notification from Advanced Technology International to halt work on a Phase 2B clinical trial for their GEO-CM04S1 COVID-19 vaccine. The termination of the contract was decided by BARDA for governmental convenience, impacting the company’s ongoing project and possibly its strategic positioning in vaccine development.

Spark’s Take on GOVX Stock

According to Spark, TipRanks’ AI Analyst, GOVX is a Underperform.

GeoVax Labs is navigating substantial financial and operational challenges. While the BARDA award and vaccine advancements are significant positives, the company’s financial instability, negative cash flow, and bearish technical indicators weigh heavily on its overall score. The mixed sentiment from the earnings call, highlighting both achievements and setbacks, contributes to a cautious outlook.

To see Spark’s full report on GOVX stock, click here.